UltraGreen.ai secures dual regulatory approvals in Philippines and Malaysia

UltraGreen.ai Limited, a Singapore-based fluorescence-guided surgery and digital health solutions firm, has announced the regulatory approvals for both its Verdye (indocyanine green for injection) in the Philippines and its IC-Flow Imaging System V2 in Malaysia. UltraGreen.ai said in a statement on Tuesday that the approvals, secured following a long and rigorous regulatory process, marks an important step in the company’s strategic expansion across Southeast Asia, a region with rapidly growing healthcare demand. It is noted that fluorescence-guided surgery using indocyanine green (ICG) has become an increasingly important tool across multiple surgical procedures and specialties. The approval of the IC-Flow Imaging System V2 in Malaysia supports the use of fluorescence imaging technology in clinical settings, while the approval of Verdye provides clinicians in the Philippines with access to a globally established, high-quality ICG product supported by extensive clinical experience across Europe, United States, Asia, and other international markets. With these approvals in place, UltraGreen and its local partners can now actively support education, training, and broader clinical adoption of ICG–based techniques among surgeons in both markets. UltraGreen said the firm is pursuing a comprehensive, regionally focused approach to building fluorescence-guided surgery. As the company continues to expand its footprint across Southeast Asia through regulatory approvals, clinical partnerships, and market access initiatives, it provides not only a high-quality imaging dye and compatible products but is also developing an artificial intelligence (AI)-powered data platform designed to further support surgical decision-making and standardization of care across multiple procedures and specialties. “These approvals represent far more than regulatory milestones – they pave the way for delivering proven surgical technologies to healthcare systems across Southeast Asia,” said Declan Cassells, Chief Operating Officer of UltraGreen. “Achieving these milestones allows us to deliver on our stated ambition of expanding our presence across Southeast Asia and importantly, to support surgeons in the region with proven fluorescence-guided solutions that can enhance clinical decision-making and patient care, “We are committed to supporting these healthcare communities with not just products, but comprehensive training and clinical support, that will elevate the standard of surgical care across the region,” he added. Quek Mei Ling, Chief Business Officer (APAC) of UltraGreen, added that Southeast Asia is seeing a rapid increase in surgical procedures across oncology, colorectal and reconstructive care. “Fluorescence-guided surgery gives surgeons real-time visualization that can be integrated easily into existing workflows, supporting better intra-operative decisions without adding infrastructure complexity, “The IC-Flow system can be used across multiple specialties, making it a highly practical tool as surgical demand continues to grow,” he added. These approvals further strengthen UltraGreen’s growing footprint in Southeast Asia and underscore the Company’s long-term commitment to advancing precision surgery through high-quality pharmaceutical, imaging and data-driven solutions, said the statement. UltraGreen.ai receives strong demand for $400M SGX IPO